Sodium Ferric Gluconate Complex

Summary

Sodium Ferric Gluconate Complex (CHEMBL1201494) is an approved unknown; indicated across 2 conditions including anemia and iron deficiency anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201494
Name	Sodium Ferric Gluconate Complex
Type	Unknown
Max phase	4

Also known as: Ferlixit, Ferric sodium gluconate complex, Osmoferrin, Sodium ferric gluconate complex, SODIUM FERRIC GLUCONATE COMPLEX

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anemia	3	MONDO:0002280	EFO:0004272
iron deficiency anemia	2	MONDO:0001356	HP:0001891

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00223977	PHASE2/PHASE3	COMPLETED	2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).